noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Jones Lang LaSalle Inc.

JLL boosts Industrials division with manufacturing and supply chain expert
Google LLC

AI’s potential to tackle the UK’s productivity puzzle
The University of Toledo

Rocket Kids to Celebrate Third Year of Global Service on Saturday

Healthcare

Impact Biomedical Inc.

04/03/2025 | Press release | Distributed by Public on 04/03/2025 14:29

Material Agreement (Form 8-K)

Item 1.01.

Entry Into a Material Definitive Agreement.

Debt Conversion Agreement

As previously reported on the Company's current report on Form 8-K, filed March 28, 2025 (the "Initial 8-K"), Impact BioMedical Inc. (the "Company") entered into a Debt Conversion Agreement (the "Debt Conversion Agreement"), dated March 24, 2025, with DSS, Inc. ("DSS"), pursuant to that certain Amended and Restated Promissory Note, dated September 16, 2024 (the "Promissory Note"). The original principal amount of the Promissory Note was $12,000,000, and as of March 24, 2025, the Promissory Note had a principal balance of $13,176,477.03.

In connection with the Initial 8-K, given current market conditions, DSS has withdrawn from the Debt Conversion Agreement at this time. As such, no shares have been issued in connection with the Debt Conversion Agreement.